Monitoring of COVID-19 Seroprevalence Among GHdC Staff Members
Covid19
About this trial
This is an interventional prevention trial for Covid19
Eligibility Criteria
Inclusion Criteria:
- To be an employee or independent collaborator at the GHdC
Exclusion Criteria:
- Refusal to take a blood test for anti-SARS-CoV-2 antibodies
Regarding amendment 1:
- Members who did not receive the third dose of PFIZER vaccine (Comirnaty) during the GHdC vaccination campaign and who did not performed a blood test to measure anti-SARS-CoV-2 antibodies.
Sites / Locations
- Grand Hôpital de Charleroi
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Other
Other
Other
Other
Other
Participants who refuse the SARS-CoV-2 vaccine
Participants who received the first dose of SARS-CoV-2 vaccine before the first serological test
Participants who start with the serological test before SARS-CoV-2 vaccine
Participants who received the third dose of SARS-CoV-2 vaccine
Participant who received the third dose of SARS-CoV-2 vaccine and
Participant who does not wish to be vaccinated against the SARS-CoV-2 virus and who wishes to perform the serological test during the vaccination campaign and the second 12-14 weeks after the first serological test.
Participant who has received his first dose of vaccine and who performs his serological test when he receives the second dose of vaccine against the SARS-CoV-2 virus to determine his immunity. The second serological test will be done 12 to 14 weeks after the second dose of the SARS-CoV-2 vaccine to determine its immunity.
Participant who performed the serological test before the first dose of vaccine and 12 to 14 weeks after the second dose of vaccine against the SARS-CoV-2 virus to determine his immunity.
Participant who performs his serological test when he receives the third dose of vaccine against the SARS-CoV-2 virus to determine his immunity.
Participant who performs a serological test between 12 and 14 weeks after the third dose of SARS-CoV-2 vaccine to determine immunity. And who has agreed to undergo serological testing prior to the third dose of the vaccine.